Business Context and Reporting Period
Envoy Medical, Inc. (formerly Anzu Special Acquisition Corp I) filed this Form 8-K on July 29, 2024. The company is an emerging growth company incorporated in Delaware with principal executive offices in White Bear Lake, MN. Its Class A Common Stock (COCH) and Redeemable Warrants (COCHW) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a Current Report regarding a material definitive agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change reported is the amendment of a Forward Purchase Agreement (FPA) entered into on April 17, 2023, with Meteora Special Opportunity Fund I, LP and related entities (collectively, the "Meteora FPA Parties").
- Agreement Amendment: On July 29, 2024, the Company and Meteora FPA Parties executed an amendment to the FPA.
- Warrant Exercise Price Floor Adjustment: The amendment modifies the exercise price floor for 3,874,394 "Shortfall Warrants" previously issued to the Meteora FPA Parties.
- 1,000,000 Warrants: Exercise price floor reduced to $2.00.
- 1,000,000 Warrants: Exercise price floor reduced to $3.00.
- Remaining Warrants: Retain the original $4.00 exercise price floor.
- Registration: The issuance and resale of the Shortfall Warrant Shares have been registered under Form S-1 (File No. 333-276590), declared effective on May 2, 2024.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the amended agreement. The text notes that the description of the FPA Amendment is qualified in its entirety by reference to the full text of the agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Review the full text of the Amendment to the Forward Stock Purchase Agreement (Exhibit 10.1) for specific terms regarding the volume weighted average price (VWAP) formula and conditions for further price floor reductions.
- Verify the total number of Shortfall Warrants outstanding and the specific allocation of the new exercise price floors ($2.00, $3.00, and $4.00).
- Confirm the status of the Form S-1 registration statement (File No. 333-276590) regarding the resale of Shortfall Warrant Shares.
- Assess the potential dilution impact on existing shareholders if the Shortfall Warrants are exercised at the new lower price floors.